An2 Therapeutics Inc (ANTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -31,052 | -16,617 | -64,732 | -47,834 | -31,127 |
| Depreciation Amortization | -1,981 | -1,091 | -2,855 | -1,549 | -896 |
| Accounts payable and accrued liabilities | -791 | -243 | 553 | 2,660 | 1,009 |
| Other Working Capital | -3,493 | -1,924 | 5,168 | 5,957 | 3,552 |
| Other Operating Activity | 5,340 | 2,282 | 8,578 | 4,546 | 3,042 |
| Operating Cash Flow | $-31,977 | $-17,593 | $-53,288 | $-36,220 | $-24,420 |
| Cash Flows From Investing Activities | |||||
| Purchase Of Investment | -12,590 | N/A | -132,178 | -112,348 | -27,136 |
| Sale Of Investment | 55,340 | 26,290 | 88,900 | 68,650 | 45,900 |
| Investing Cash Flow | $42,750 | $26,290 | $-43,278 | $-43,698 | $18,764 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 124 | 349 | 84,994 | 85,315 | 19,249 |
| Common Stock Repurchased | 225 | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $349 | $349 | $84,994 | $85,315 | $19,249 |
| Beginning Cash Position | 15,647 | 15,647 | 27,219 | 27,219 | 27,219 |
| End Cash Position | 26,769 | 24,693 | 15,647 | 32,616 | 40,812 |
| Net Cash Flow | $11,122 | $9,046 | $-11,572 | $5,397 | $13,593 |
| Free Cash Flow | |||||
| Operating Cash Flow | -31,977 | -17,593 | -53,288 | -36,220 | -24,420 |
| Free Cash Flow | -31,977 | -17,593 | -53,288 | -36,220 | -24,420 |